Qiagen NV suspended its full-year 2026 guidance on October 21 as it awaits completion of its transaction with EQT Private Equity. The Netherlands-based molecular biology company, listed on the NYSE under QGEN, will also forgo a conference call on its third-quarter results.
Key Takeaways
- Qiagen suspended its 2026 outlook while the EQT Private Equity transaction remains pending.
- The company will not hold a conference call to discuss third-quarter results.
Table of Contents
Qiagen outlook suspended during acquisition process
Qiagen supplies molecular biology products for life sciences research and molecular diagnostics. Its portfolio includes sample collection products, nucleic acid extraction kits, assays, instruments and bioinformatics software.
Qiagen’s market capitalization was $10.30 billion. Its trailing 12-month price-to-earnings ratio was 25.39 times, slightly below its five-year median of 26.76 times.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
